Abstract
The blood coagulation cascade is an integral part of hemostasis, a biological process evolved as important defense mechanism to prevent bleeding from a damaged vessel and to restore vascular integrity. By taking place on the surface of activated platelets, aim of coagulation is to generate fibrin meshes that stabilize the platelet plug and thus stop blood loss. Under normal conditions, anticoagulant mechanisms ensure careful control of coagulation and they prevail over the procoagulant forces. Aberrant activation of coagulation can, however, lead to the formation of intravascular clots that underpin pathological thrombotic disorders, including myocardial infarction, stroke, and venous thromboembolism.
In the present chapter, the modern cell-based model of blood coagulation is described emphasizing the different mechanism of action of oral anticoagulants and the related consequences.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Barrett AJ, Starkey PM. The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J. 1973;133(4):709–24.
Bom VJ, Bertina RM. The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. Biochem J. 1990;265(2):327–36.
Brambilla M, et al. Human megakaryocytes confer tissue factor to a subset of shed platelets to stimulate thrombin generation. Thromb Haemost. 2015;114(3):579–92.
Camera M, et al. Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs. Arterioscler Thromb Vasc Biol. 2003;23(9):1690–6.
Camera M, et al. Tissue factor expression on platelets is a dynamic event. Blood. 2010;116(23):5076–7.
Camera M, et al. The role of tissue factor in Atherothrombosis and coronary artery disease: insights into platelet tissue factor. Semin Thromb Hemost. 2015;41(7):737–46.
Dargaud Y, et al. Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels. J Thromb Haemost. 2013;11(6):1043–52.
Davidson CJ, Tuddenham EG, McVey JH. 450 million years of hemostasis. J Thromb Haemost. 2003;1(7):1487–94.
Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989;134(5):1087–97.
Fleck RA, et al. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res. 1990;59(2):421–37.
Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359(9):938–49.
Giugliano RP, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.
Granger CB, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.
Hankey GJ, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke. 2014;45(5):1304–12.
Hart RG, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43(6):1511–7.
Haynes LM, Orfeo T, Mann KG. Rivaroxaban delivery and reversal at a venous flow rate. Arterioscler Thromb Vasc Biol. 2012;32(12):2877–83.
Hoffman M, Monroe DM. Impact of non-vitamin K antagonist Oral anticoagulants from a basic science perspective. Arterioscler Thromb Vasc Biol. 2017;37(10):1812–8.
Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature. 2000;407(6806):923–6.
Jerkeman A, et al. Correlation between different intensities of anti-vitamin K treatment and coagulation parameters. Thromb Res. 2000;98(6):467–71.
Kamisato C, Furugohri T, Morishima Y. A direct thrombin inhibitor suppresses protein C activation and factor Va degradation in human plasma: possible mechanisms of paradoxical enhancement of thrombin generation. Thromb Res. 2016;141:77–83.
Kirchhofer D, Nemerson Y. Initiation of blood coagulation: the tissue factor/factor VIIa complex. Curr Opin Biotechnol. 1996;7(4):386–91.
Lentz BR. Exposure of platelet membrane phosphatidylserine regulates blood coagulation. Prog Lipid Res. 2003;42(5):423–38.
Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost. 2001;86(1):66–74.
Smith SA, Travers RJ, Morrissey JH. How it all starts: initiation of the clotting cascade. Crit Rev Biochem Mol Biol. 2015;50(4):326–36.
Tilley R, Mackman N. Tissue factor in hemostasis and thrombosis. Semin Thromb Hemost. 2006;32(1):5–10.
van Es N, et al. Clinical significance of tissue factor-exposing microparticles in arterial and venous thrombosis. Semin Thromb Hemost. 2015;41(7):718–27.
von Bruhl ML, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209(4):819–35.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Camera, M. (2021). The Coagulative Cascade. In: Proietti, R., AlTurki, A., Ferri, N., Russo, V., Bunch, T.J. (eds) Direct Oral Anticoagulants. Springer, Cham. https://doi.org/10.1007/978-3-030-74462-5_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-74462-5_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-74461-8
Online ISBN: 978-3-030-74462-5
eBook Packages: MedicineMedicine (R0)